Kliničke studije za Миозитис u državi Ilinois
6 studija za Миозитис traži učesnike na lokacijama u državi Ilinois.
Gradovi u državi Ilinois
Zvanični tekst studije (na engleskom)
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
Тражи се учесникФаза 2/3
Узраст од 6 до 75 · Оба пола · Ажурирано 13. 11. 2026. · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Chicago, Department of Medicine: Rheumatology, Chicago
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07103746A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 10. 11. 2026. · NCT07295847A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Тражи се учесникФаза 1
Узраст од 18 до 74 · Оба пола · Ажурирано 2. 11. 2026. · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 26. 10. 2026. · NCT06925542AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 31. 7. 2026. · NCT06991114Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.